Whistler Conference Centre Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2007



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

HIV Vaccines: From Basic Research to Clinical Trials (X7)


Organizer(s) Dennis R. Burton, Alexandra Trkola and David I. Watkins
March 25—30, 2007
Whistler Conference Centre • Whistler, British Columbia Canada
Abstract Deadline: Nov 27, 2006
Late Abstract Deadline: Dec 27, 2006
Scholarship Deadline: Nov 27, 2006
Early Registration Deadline: Jan 25, 2007

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation; Sponsored by Wyeth Vaccines Research


Summary of Meeting:
The development of a successful vaccine against HIV-1 faces enormous hurdles. The generation of immunogens able to elicit broadly-reactive neutralizing antibodies in humans remains elusive. The mechanisms responsible for the strong protection seen in macaques vaccinated with attenuated viruses are unknown. Furthermore, we do not fully understand why this virus persists or how some individuals control virus. The nature of transmitted viruses is still unclear. The meeting will focus on recent advances in the understanding of the interplay between the virus and the immune system that are of particular relevance for vaccine design. Leading experts in the field will provide us with insight into key findings in the area of cellular and humoral immunity to HIV, the design of novel immunogens and the mechanism of live attenuated vaccine protection. A strong emphasis of the meeting will also be on recent progress in human vaccine trials.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 25

15:00—19:30
Registration

Foyer
18:30—19:30
Refreshments

Foyer
19:30—21:30
Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online.

Ballroom B/C
Richard A. Koup, NIAID, National Institutes of Health, USA
Immunopathogenesis of HIV Infection

Jonathan W. Yewdell, NIAID, National Institutes of Health, USA
Gained in Translation: Defective Ribosomal Products (DRiPs) as a Principal Source of MHC Class I Peptide Ligands


MONDAY, MARCH 26

07:00—08:00
Breakfast

Foyer, Ballroom A, Lower Level
08:00—11:15
Transmission and New Infection (Joint)
Meeting has ended...abstracts no longer viewable online.

Ballroom B/C
* Julie M. Overbaugh, Fred Hutchinson Cancer Research Center, USA

Dorothy A. Mbori-Ngacha, University of Nairobi School of Medicine, Kenya
Mother-to-Child Transmission: From Research Policy to Implementation

Douglas D. Richman, University of California, San Diego, USA
HIV Transmission

Cynthia A. Derdeyn, Emory University, USA
Immune Escape in Early Subtype C Infection

Yang Liu, Monogram Biosciences, USA
Short Talk: Neutralization and Envelope Sequence Characteristics of a Subtype B HIV-1 Sexual Transmission Cluster: One Source and Four Recipients

Guido Silvestri, Emory University School of Medicine, USA
Understanding the Benign Nature of SIV Infection in Natural Hosts

Fran Van Heuverswyn, Institute of Research for Development (IRD), France
Short Talk: SIV Infection in Wild Gorillas and Chimpanzees in Cameroon

09:20—09:40
Coffee Break

Grand Foyer
11:15—13:00
Poster Setup

Grand Foyer/Mountain View/Ballroom A
13:00—22:00
Poster Viewing

Grand Foyer/Mountain View/Ballroom A
14:00—16:30
Workshop 1: Molecular Interactions and Virus Replication

Ballroom C
* Thomas J. Hope, Northwestern University, Feinberg School of Medicine, USA

Éric A. Cohen, Institut de Recherches Cliniques de Montréal, Canada
Productive HIV-1 Assembly Takes Place at the Plasma Membrane

Stuart G. Turville, WMI, University of Sydney, Australia
Dynamic Visualization of HIV-1 Intracellular Production, Assembly and Polarized Budding in Immature Dendritic Cells.

Olivier Schwartz, Institut Pasteur, France
Lymphocyte Activation, HIV Cell-to-Cell Spread and Virological Synapse Formation

Dmitri Ivanov, University of Texas Health Science Center, USA
Domain-Swapped Dimerization of the HIV Capsid C-Terminal Domain.

Sonia Jiménez-Baranda, National Center of Biotechnology, Spain
Filamin A (ABP280) Coordinates Actin Cytoskeleton Remodeling Required for HIV-1 Infection

Michael J. Root, Thomas Jefferson University, USA
Asymmetry in HIV-1 Inactivation Following Inhibitor Binding to gp41

Yuanfei Wu, Yale University School of Medicine, USA
Vpx Ubiquitination Modulates SIV Replication in Macrophages

Shari M. Kaiser, Institute for Systems Biology, USA
Human Trim5alpha Restriction of an Extinct Retrovirus

16:30—17:00
Coffee Available

Grand Foyer
17:00—19:15
Host and Viral Genetics
Meeting has ended...abstracts no longer viewable online.

Ballroom C
Harmit S. Malik, Fred Hutchinson Cancer Research Center, USA
Evolutionary Studies of Intrinsic Immunity against Retroviruses in Primate Genomes

Mary Carrington, Frederick National Laboratory for Cancer Research, USA
The Impact of Variation at the HLA and KIR Gene Clusters on HIV Disease

* Steven Wolinsky, Northwestern University, USA
Viral Genetic Diversity and Adaptation

John P. Moore, Weill Medical College of Cornell University, USA
Small Molecule CCR5 Inhibitor Resistant Viruses Use CCR5 Inhibitor Complex as an Entry Coreceptor

17:00—19:15
Live Attenuated Vaccines
Meeting has ended...abstracts no longer viewable online.

Ballroom B
* Ronald C. Desrosiers, University of Miami Miller School of Medicine, USA
Use of gamma-2 Herpesviruses as Vaccine Viruses for AIDS

Louis J. Picker, Oregon Health & Science University, USA
The Cellular Immune Response in Macaques Infected with Attenuated SIV

Jeffrey D. Lifson, Leidos Biomedical Research, Inc., USA
Insights into Control of Pathogenic Viral Replication by Pharmacological Modulation of Virus/Host Balance in Primary SIV Infection?

Marjorie Robert-Guroff, NCI, National Institutes of Health, USA
Prime/Boost HIV Vaccine Strategies Based on Replication Competent Adenovirus Recombinants

19:00—20:00
Social Hour with Lite Bites

Grand Foyer/Mountain View/Ballroom A
19:30—22:00
Poster Session 1

Grand Foyer/Mountain View/Ballroom A

TUESDAY, MARCH 27

07:00—08:00
Breakfast

Foyer, Ballroom A, Lower Level
08:00—11:00
Immune Responses and HIV Vaccine Development
Meeting has ended...abstracts no longer viewable online.

Ballroom B
* David I. Watkins, University of Miami, Miller School of Medicine, USA
Vaccine-Induced Cellular Immune Responses in Monkeys

Philip J. Goulder, University of Oxford, UK
CD8 T-Cell-Mediated Control of the C Clade HIV Epidemic in Sub-Saharan Africa

Otto O. Yang, University of California, Los Angeles, USA
Interactions of Nef and CTL

John R. Mascola, NIAID, National Institutes of Health, USA
Epitope Specific Neutralizing Antibody Responses

Galit Alter, Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Significant Inhibition of HIV-1 Replication by KIR3DS1+ NK Cells Derived From KIR3DS1+/HLA-Bw480I+ Individuals

08:00—11:00
Intracellular Events (Early and Late)
Meeting has ended...abstracts no longer viewable online.

Ballroom C
* Robert W. Doms, University of Pennsylvania School of Medicine, USA

James J. Champoux, University of Washington, USA
Reverse Transcription: Displacement Synthesis, RNase H, and Recombination

John V. Moran, University of Michigan Medical School, USA
Genetic and Biochemical Studies of LINE-1 Retrotransposition

Eric Poeschla, University of Colorado School of Medicine, USA
Short Talk: LEDGF/p75: Testing the HIV Integration Cofactor Role in Multiple T Cell Lines and Primary Macrophages

Katherine A. Jones, The Salk Institute, USA
HIV Tat and Transcription

Paul D. Bieniasz, Aaron Diamond AIDS Research Center, USA
Host Restriction of Retrovirus Replication

09:20—09:40
Coffee Break

Grand Foyer
11:00—13:00
Poster Setup

Grand Foyer/Mountain View/Ballroom A
13:00—22:00
Poster Viewing

Grand Foyer/Mountain View/Ballroom A
14:00—16:30
Workshop 2: gp41 as an HIV Vaccine Target

Ballroom B
Gilad A. Ofek, National Institutes of Health, USA
Epitope-Scaffold Immunogens: Design, Characterization, and Molecular Mimicry of the 2F5 Epitope

Jean-Philippe Julien, Hospital for Sick Children Research Institute, Canada
Structural Insights into the Mechanism of Neutralization of the nmAb 2F5 Against HIV-1: Conformations of the 2F5 CDR3 Extended Loop and Residues Located at the C-Terminus of the DKW Core

Michael B. Zwick, The Scripps Research Institute, USA
Antibodies Against the N-heptad Repeat Hydrophobic Pocket Region of gp41 are Elicited During Natural Infection and by Immunization But Sterics Can Restrict Neutralization of Primary HIV-1

Marinieve Montero, CFRI/University of British Columbia, Canada
Immunogenicity of the Membrane Proximal External Region of HIV-1 gp41 in the Context of the Cell Surface

Sylvain Fleury, Mymetics Corporation, Switzerland
Without Mucosal Adjuvant, Virosomes-gp41 Peptides from the MPR can Elicit Protective Mucosal IgA in Vaccinated Macaques.

Carl R. Alving, Walter Reed Army Institute of Research, USA
Neutralizing Effects on HIV-1 of Murine and Human Monoclonal Antibodies That Bind to Phosphatidylinositol-4-phosphate

* Jamie K. Scott, Simon Fraser University, Canada
Reactivity Profiles of HIV-1-Neutralizing MAbs, 2F5 and 4E10, and the Anti-Cardiolipin MAb, CL15

Xiaoying Shen, Duke University Medical Center, USA
Analysis of a Rare HIV Envelope Sequence that is Highly Sensitive to Broadly Neutralizing Antibodies 2F5 and 4E10

Christopher J. Richards, National Cancer Institute, National Institutes of Health, USA
Activity of an Affordable Fusion Inhibiting Peptide

* Carol D. Weiss, US Food and Drug Administration, USA
Novel Mechanism of Resistance to HIV-1 Peptide Fusion Inhibitors

16:30—17:00
Coffee Available

Grand Foyer
17:00—19:00
HIV Vaccine Program Updates
Meeting has ended...abstracts no longer viewable online.

Ballroom B
* Douglas D. Richman, University of California, San Diego, USA

Barton F. Haynes, Duke University Medical Center, USA
Update On CHAVI B Cell and Transmitted Virus Discovery Programs

Wayne C. Koff, International AIDS Vaccine Initiative, USA
IAVI R&D Program Update: Fostering Innovation in AIDS Vaccine Discovery and Development

Gary J. Nabel, Sanofi, USA
Pushing the Envelope of HIV Vaccines: From Basic Research to Clinical Trials

17:00—19:00
Restriction Factors
Meeting has ended...abstracts no longer viewable online.

Ballroom C
* Paul D. Bieniasz, Aaron Diamond AIDS Research Center, USA

Greg J. Towers, University College London, UK
TRIMs, Cyclophilins and Restriction of Retroviral Infection

Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA
New Perspectives on APOBEC3G Biology

Didier Trono, Ecole Polytechnique Fédérale de Lausanne, Switzerland
Repression Insights into the Mechanisms of Action of Intrinsic Immune Antivirals

Max W. Richardson, University of Pennsylvania, USA
Short Talk: Mode of Transmission Affects Sensitivity of HIV-1 to rTRIM5alpha Restriction

19:00—20:00
Social Hour with Lite Bites

Grand Foyer/Mountain View/Ballroom A
19:30—22:00
Poster Session 2

Grand Foyer/Mountain View/Ballroom A

WEDNESDAY, MARCH 28

07:00—08:00
Breakfast

Foyer, Ballroom A, Lower Level
08:00—11:00
Structures (Joint)
Meeting has ended...abstracts no longer viewable online.

Ballroom B/C
* Dennis R. Burton, The Scripps Research Institute, USA

Peter D. Kwong, NIAID, National Institutes of Health, USA
A Structural Approach to Vaccine Design

Stephen C. Harrison, Harvard Medical School, USA
HIV and SIV Env Glycoproteins

Ian A. Wilson, The Scripps Research Institute, USA
HIV Neutralizing Antibody Structures

Wesley I. Sundquist, University of Utah School of Medicine, USA
Mechansims of HIV Budding

Harold C. Smith, University of Rochester, USA
Short Talk: Nanostructures of APOBEC3G Support a Hierarchical Assembly Model of High Molecular Mass Ribonucleoprotein Particles from Dimeric Subunits

09:20—09:40
Coffee Break

Grand Foyer
11:00—13:00
Poster Setup

Grand Foyer/Mountain View/Ballroom A
13:00—22:00
Poster Viewing

Grand Foyer/Mountain View/Ballroom A
14:00—16:30
Workshop 3: Pathogenesis and Immune Responses

Ballroom C
* Richard A. Koup, NIAID, National Institutes of Health, USA

Anna Duda, University of Oxford, UK
A Cohort Study of HIV Adaptation and Reversion in the First Three Years After Transmission to New Hosts

Joe Casazza, NIAID, National Institutes of Health, USA
Evidence of a Protective Role for Cytokine/Chemokine Production in HIV Infection

Daniel E. Kaufmann, University of Montreal, Canada
CTLA-4 upregulation in HIV-specific CD4 T cells correlates with disease progression and defines a reversible immune dysfunction

Beda Brichacek, National Cancer Institute, USA
The Effect of TLR Ligands on HIV-1 Replication in Human Lymphoid Tissue ex vivo: A Potential Mechanism of Co-Pathogenesis

Richard T. Lester, University of Manitoba and University of British Columbia, Canada
Elevated Toll-like Receptor (TLR) Expression and Altered Cytokine Responses to TLR Ligands in Peripheral Blood Leukocytes of HIV-1 Positive Patients.

Judith N. Mandl, National Institutes of Health, USA
Investigating the Role of TLR7&9 Stimulation in Chronic Immune Activation during SIV Infection of Rhesus Macaques

Nichole R. Klatt, University of Washington, USA
The Main Determinant of Set-Point Viremia During Natural SIV Infection of Sooty Mangabeys is the Number of Activated CD4+ T Cells

Meritxell Genescà, Health Sciences Research Institute Germans Trias i Pujol Foundation, Spain
Live-Attenuated Lentivirus Immunization Mediated Protection of Rhesus Macaques From Intravaginal SIV Challenge is Associated With Survival and Polyfunctional Capacity of SIV-Specific CD8+ T Cell

Donald L. Sodora, Center for Infectious Disease Research, USA
Gamma/Delta T Cell Function is Impaired During HIV-Infection but Not During Nonpathogenic SIV-Infection of Sooty Mangabeys

16:30—17:00
Coffee Available

Grand Foyer
17:00—19:00
Relevant Lessons from Other Systems
Meeting has ended...abstracts no longer viewable online.

Ballroom B
Kasper Hoebe, The Scripps Research Institute, USA
The Innate-Adaptive Connection: TLRs and Beyond

Annette Oxenius, Institute for Microbiology, ETH Zürich, Switzerland
CD8+ T Cell Dysfunction during Chronic Viral Infections

Richard T. Wyatt, IAVI Neutralizing Antibody Center at The Scripps Research Institute, USA
HIV-1 gp120 Structure-based Immunogen Design

David Price, Cardiff University School of Medicine, UK
Short Talk: Evolution of Cytomegalovirus-Specific CD4+ T Cell Clonotypes in vivo: Vaccine Design Informed by Successful Immune Responses

17:00—19:00
Viral Assembly, Viral Synapse & Cell Biology
Meeting has ended...abstracts no longer viewable online.

Ballroom C
* Charles R.M. Bangham, Imperial College Department of Medicine, UK

Anthony L. Cunningham, Westmead Institute for Medical Research, Australia
Modulation of Dendritic Cell Function by HIV: Implications for Initial Infection and Pathogenesis

Thomas J. Hope, Northwestern University, Feinberg School of Medicine, USA
Mechanism of Restriction Mediated by TRIM5 alpha

Paul W. Spearman, Emory University, USA
Cellular Trafficking Pathways and the Role of Vpu in Retrovirus Assembly

Juan Martin-Serrano, King's College London School of Medicine, UK
Short Talk: Interaction of Tsg101 With Components of the Cytokinesis Machinery and Role in Viral Budding

19:00—20:00
Social Hour with Lite Bites

Grand Foyer/Mountain View/Ballroom A
19:30—22:00
Poster Session 3

Grand Foyer/Mountain View/Ballroom A

THURSDAY, MARCH 29

07:00—08:00
Breakfast

Foyer, Ballroom A, Lower Level
08:00—11:00
Mechanisms of Viral Persistence and Immune Avoidance (Joint)
Meeting has ended...abstracts no longer viewable online.

Ballroom B/C
Alan N. Engelman, Dana-Farber Cancer Institute, USA
Host Factors and HIV-1 Integration

Charles R.M. Bangham, Imperial College Department of Medicine, UK
Efficiency of the Anti-Viral CTL Response: HTLV-1

Alexandra Trkola, University of Zürich, Switzerland
Prospects of Humoral Immunity to HIV-1

Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
Elite Control of HIV: Implications for Vaccine Design

Jason M. Brenchley, NIAID, National Institutes of Health, USA
Short Talk: Microbial Translocation is a Cause of Systemic Immune Activation in Chronic HIV Infection

09:20—09:40
Coffee Break

Grand Foyer
11:00—12:00
Poster Setup

Grand Foyer/Mountain View/Ballroom A
11:00—12:00
Lunch

Grand Foyer/Mountain View/Sky Ballroom A
12:00—16:30
Poster Session 4

Grand Foyer/Mountain View/Ballroom A
14:00—16:30
Workshop 4: CTL Function, Dysfunction and Escape

Ballroom B
* Marcus Altfeld, Heinrich-Pette-Institute, Germany

* Otto O. Yang, University of California, Los Angeles, USA

Tedi E. Asher, NIAID, National Institutes of Health, USA
Clonal Correlates of Vaccine-Induced Immune Protection Against SIV in Rhesus Macaques

Sylvie Le Gall, Massachusetts General Hospital, Harvard Medical School, USA
Intracellular Epitope Stability is Defined by Specific Residues and Correlates With HIV Epitope Hierarchy

Emma L. Turnbull, Jenner Institute, University of Oxford, UK
Mutational Escape, Rather than Reduced Avidity of Epitope-Specific T Cell Responses, may be More Relevant for Impairment of the HIV-Specific CD8+ T Cell Response During Early HIV-1 Infection

Jonah B. Sacha, Oregon Health & Science University, USA
Gag-Specific CD8+ T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression

Hendrik Streeck, Military HIV Research Program, USA
Immunodomination by HLA-B27/-B57 Results in a Substantial Abrogation of Alternate HLA-Restricted HIV-Specific Responses in Primary HIV-1 Infection

Hayley Crawford, Oxford University, UK
Compensatory Mutation Restores Fitness and Delays Reversion of Escape Mutation within the Immunodominant HLA-B*5703-Restricted Gag Epitope in Chronic HIV Infection

Nicole Frahm, Fred Hutchinson Cancer Research Center, USA
Preferential Targeting of HIV-Gag Epitopes in Elite Controllers

Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V., Netherlands
Differential Clinical Course in HLA B57+ Long-Term Nonprogressors and Progressors Does not Relate to Frequencies of Gag Specific Cytotoxic T Lymphocytes or Sequence Dynamics in Gag CTL Epitopes but to HIV-1 Replicative Capacity

Stephen A. Migueles, NIAID, National Institutes of Health, USA
Diminished Proliferative Capacity of HIV-Specific CD8+ T Cells is not Restored by Antiretroviral Therapy or Exogenous IL-2

Teresa Lea Mattila, University of Minnesota, USA
In Situ Analysis of Virus-Specific CD8+ T Cells

16:30—17:00
Coffee Available

Grand Foyer
17:00—19:00
Novel Immunogens
Meeting has ended...abstracts no longer viewable online.

Ballroom B
* Ian A. Wilson, The Scripps Research Institute, USA

Hiroyuki Yamamoto, Institute of Medical Science, The University of Tokyo, Japan
SIV Control by Post-Infection Passive Immunization of Neutralizing Antibodies

Ping Zhu, Florida State University, USA
3D HIV-1 Envelope Spike Model as Revealed by Cryoelectron Tomography

Giulia Zanetti, Wellcome Trust Centre, University of Oxford, UK
Cryo-Electron Tomography of SIV Envelope Complex in situ

Sriram Subramaniam, National Institutes of Health, USA
Electron Tomography of Immunodeficiency Viruses and Structural Mechanisms of Cellular Entry

Quentin J. Sattentau, Sir William Dunn School of Pathology, UK
Increasing HIV-1 Env Immunogenicity by Modulation of Intrinsic and Extrinsic Factors

17:00—19:15
Drugs and Viral Fitness
Meeting has ended...abstracts no longer viewable online.

Ballroom C
* Michael H. Malim, King's College London, UK

Daniel R. Kuritzkes, Brigham and Women's Hospital, Harvard Medical School, USA
Drug Resistance and Viral Fitness in HIV-1

David Heckerman, Human Longevity, Inc., USA
Short Talk: Estimate of the Proportion of Within-Host Sequence Evolution in HIV-1 Mediated by Human Leukocyte Antigen (HLA) Class I Selective Pressures

Celia C. LaBranche, Global Vaccines, Inc., USA
Development of CCR5 Antagonists as HIV Antiviral Drugs

Laura A. Napolitano, Gladstone Institute of Virology and Immunology, USA
Short Talk: Growth Hormone Therapy Enhances Thymic Function in HIV-infected Adults: A Randomized Prospective Analysis

Yonchu Jenkins, Rigel Pharmaceuticals, Inc., USA
Short Talk: Identification of Novel Antiretroviral Compounds by Targeting HIV Vif Function

19:00—20:00
Social Hour with Lite Bites

Grand Foyer/Mountain View/Ballroom A
20:00—23:00
Entertainment

Grand Foyer/Mountain View/Ballroom A

FRIDAY, MARCH 30

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 5 R13 AI068371-02




We gratefully acknowledge additional support for this conference from:

Bill & Melinda Gates Foundation International AIDS Vaccine Initiative (IAVI)
Office of AIDS Research, NIH Wyeth Vaccines Research

GenVec, Inc.
 

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676